Longeveron Inc. (NASDAQ: LGVN) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT LONGEVERON INC.

Longeveron Inc. (NASDAQ: LGVN)
Listen to this Section


$1.51
+0.0100 ( -0.66% ) 50.0K

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Market Data


Open $1.51
Previous Close $1.50
Volume 50.0K
Market Cap $22.55M
Day Range $1.48 - $1.62
52 Week Range $0.77 - $6.40
Shares Outstanding 14.84M
Change % -0.66%
Net Change ▲ 0.0100
Insider Ownership -0.11%
Exchange NASDAQ
Sector Healthcare
Industry Medicinal Chemicals and Botanical Products
IPO Year 2021
Country United States
Under Writer IPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -171,345.00

Date Type Amount Purchased Purchaser
2024-08-07 Sale -16000.00 Hajjar Roger Joseph
2024-08-07 Sale -16000.00 Motwani Neha J.
2024-07-03 Sale -357.00 Locklear Lisa
2024-06-11 Sale -125.00 Baluch Khoso
2024-06-07 Sale -325.00 Lehr Paul T
2024-05-14 Sale -16000.00 Kender Richard N
2024-05-06 Sale -410.00 Locklear Lisa
2024-05-06 Sale -308.00 Agafonova Nataliya
2024-04-12 Buy 10638.00 Hashad Mohamed Wa'el Ahmed
2024-04-12 Buy 106383.00 Soffer Rock

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Jun 07, 2024
424b3 Other 5 May 22, 2024
effect Other 1 May 21, 2024
s-1/a Registration statements 20 May 21, 2024
ars Annual reports 1 May 20, 2024
def Proxies and info statements 4 May 20, 2024
defa14a Other 2 May 20, 2024
corresp Comment letters 1 May 17, 2024
4 Insider transactions 1 May 14, 2024
10-q Quarterly Reports 72 May 14, 2024

Latest News


× Before browsing our site, please accept our cookies policy